Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
Editas was the first of three gene editing biotechs to make a splash on Nasdaq and up until this week it also looked like it was in the lead in the race to be the first in the group to make it into a groundbreaking human study.
On Monday Editas $EDIT CEO Katrine Bosley said that a “manufacturing delay related to production of input materials for AAV manufacturing” forced the company to delay their planned IND filing to the middle of next year. As execs explained it, one of the input materials used in making their delivery vehicle failed a quality control inspection, and the delay in fixing that caused them to lose their time slot with the CMO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.